Written by
Mustafa Çelik
Mustafa Çelik Liv Hospital Content Team
Medically reviewed by

Related Doctors

Assoc. Prof. MD. Evrim Duman Liv Hospital Ulus Assoc. Prof. MD. Evrim Duman Radiation Oncology Asst. Prof. MD. Meltem Topalgökçeli Selam Liv Hospital Ulus Asst. Prof. MD. Meltem Topalgökçeli Selam Medical Oncology Prof. MD. Duygu Derin Liv Hospital Ulus Prof. MD. Duygu Derin Medical Oncology Prof. MD. Emre Merdan Fayda Liv Hospital Ulus Prof. MD. Emre Merdan Fayda Radiation Oncology Prof. MD. Meral Günaldı Liv Hospital Ulus Prof. MD. Meral Günaldı Medical Oncology Assoc. Prof. MD. Murat Ayhan Liv Hospital Vadistanbul Assoc. Prof. MD. Murat Ayhan Medical Oncology Prof. MD.  Itır Şirinoğlu Demiriz Liv Hospital Vadistanbul Prof. MD. Itır Şirinoğlu Demiriz Hematology Prof. MD. Tülin Tıraje Celkan Liv Hospital Vadistanbul Prof. MD. Tülin Tıraje Celkan Pediatric Hematology and Oncology Assoc. Prof. MD. Erkan Kayıkçıoğlu Liv Hospital Bahçeşehir Assoc. Prof. MD. Erkan Kayıkçıoğlu Medical Oncology Assoc. Prof. MD. Mine Dağgez Liv Hospital Bahçeşehir Assoc. Prof. MD. Mine Dağgez Gynecological Oncology Assoc. Prof. MD. Ozan Balakan Liv Hospital Bahçeşehir Assoc. Prof. MD. Ozan Balakan Medical Oncology MD. Taylan Bükülmez Liv Hospital Bahçeşehir MD. Taylan Bükülmez Radiation Oncology Op. MD. Alp Koray Kinter Liv Hospital Bahçeşehir Op. MD. Alp Koray Kinter Gynecological Oncology Prof. MD. Nuri Faruk Aykan Liv Hospital Bahçeşehir Prof. MD. Nuri Faruk Aykan Medical Oncology Prof. MD. Yasemin Altuner Torun Liv Hospital Bahçeşehir Prof. MD. Yasemin Altuner Torun Pediatric Hematology and Oncology Spec. MD. Özlem Doğan Liv Hospital Bahçeşehir Spec. MD. Özlem Doğan Medical Oncology Assoc. Prof. MD. Emir Çelik Liv Hospital Topkapı Assoc. Prof. MD. Emir Çelik Medical Oncology Assoc. Prof. MD. Muhammed Mustafa Atcı Liv Hospital Topkapı Assoc. Prof. MD. Muhammed Mustafa Atcı Medical Oncology Prof. MD. İrfan Çiçin Liv Hospital Topkapı Prof. MD. İrfan Çiçin Medical Oncology Assoc. Prof. MD.  Ramazan Öcal Liv Hospital Ankara Assoc. Prof. MD. Ramazan Öcal Hematology Assoc. Prof. MD. Nazlı Topfedaisi Özkan Liv Hospital Ankara Assoc. Prof. MD. Nazlı Topfedaisi Özkan Gynecological Oncology Prof. MD. Fikret Arpacı Liv Hospital Ankara Prof. MD. Fikret Arpacı Medical Oncology Prof. MD. Gökhan Erdem Liv Hospital Ankara Prof. MD. Gökhan Erdem Medical Oncology Prof. MD. Meral Beksaç Liv Hospital Ankara Prof. MD. Meral Beksaç Hematology Prof. MD. Oral Nevruz Liv Hospital Ankara Prof. MD. Oral Nevruz Hematology Prof. MD. Saadettin Kılıçkap Liv Hospital Ankara Prof. MD. Saadettin Kılıçkap Medical Oncology Prof. MD. Sadık Muallaoğlu Liv Hospital Ankara Prof. MD. Sadık Muallaoğlu Medical Oncology Spec. MD. Ender Kalacı Liv Hospital Ankara Spec. MD. Ender Kalacı Medical Oncology Assoc. Prof. MD. Fadime Ersoy Dursun Liv Hospital Gaziantep Assoc. Prof. MD. Fadime Ersoy Dursun Hematology Prof. MD. Fatih Teker Liv Hospital Gaziantep Prof. MD. Fatih Teker Medical Oncology Spec. MD. ELXAN MEMMEDOV Liv Bona Dea Hospital Bakü Spec. MD. ELXAN MEMMEDOV Medical Oncology Spec. MD. Ceyda Aslan Spec. MD. Ceyda Aslan Hematology Spec. MD. Elkhan Mammadov Spec. MD. Elkhan Mammadov Medical Oncology Spec. MD. Elmir İsrafilov Spec. MD. Elmir İsrafilov Hematology Spec. MD. Minure Abışova Eliyeva Spec. MD. Minure Abışova Eliyeva Hematology Spec. MD. Natavan Azizova Spec. MD. Natavan Azizova Medical Oncology Prof. MD. Mehmet Hilmi Doğu Liv Hospital Ulus + Liv Hospital Bahçeşehir Prof. MD. Mehmet Hilmi Doğu Hematology
...
Views
Read Time
...
views
Read Time
Which Treatment Would Most Likely Be Used for Cancer 2025?
Which Treatment Would Most Likely Be Used for Cancer 2025? 4

Looking ahead to 2025, the world of cancer treatment is changing fast. Experts predict big steps forward, like better immunotherapy and targeted therapies. When considering which treatment would most likely be used for cancer, immunotherapy, targeted therapies, hormone therapy, and personalized cancer vaccines are gaining prominence, offering more precise and effective options tailored to individual patient profiles.

The way we treat cancer is changing a lot. Now, we focus more on care that fits each person. The 5-year survival rate for cancer patients is now 91 percent. This shows how far we’ve come in finding new treatments.

Immunotherapies, targeted therapies, and precision medicine are leading this change. They bring new hope to people all over the world.

Key Takeaways

  • Advances in immunotherapy and targeted therapies are expected to continue in 2025.
  • The 5-year relative survival rate for cancer patients has reached 91 percent.
  • Precision medicine is becoming increasingly important in cancer treatment.
  • Personalized care is becoming a growing emphasis in cancer treatment.
  • Cancer treatment is rapidly evolving with new innovations.

The Evolving Landscape of Cancer Treatment

Which Treatment Would Most Likely Be Used for Cancer 2025?
Which Treatment Would Most Likely Be Used for Cancer 2025? 5

The way we treat cancer is changing fast. New medical tech and a better understanding of cancer are leading the way. We’re moving towards treatments that are more personal, effective, and innovative.

Current Challenges in Cancer Therapy

Even with progress, challenges in cancer treatment remain. One big issue is therapy resistance, which makes treatments less effective over time. Also, cancer’s diversity means one treatment might not work for everyone.

New radiation treatments are making therapy shorter and catching cancer earlier, as MD Anderson Research News reports. Yet, we need treatments that are more precise and have fewer side effects.

ChallengeDescriptionPotential Solution
Resistance to TherapyReduced efficacy of treatments over timeDevelopment of new, targeted therapies
Cancer HeterogeneityVariability in cancer cells within and among patientsPersonalized medicine approaches
Treatment Side EffectsNegative impacts on quality of lifeAdvancements in supportive care and precision medicine

Rising Survival Rates and Treatment Efficacy

Survival rates for cancer are going up thanks to better detection and treatments. Immunotherapies and targeted therapies are leading this change. They offer better and less harmful options.

We must keep making treatments more effective while tackling new therapy challenges. Precision medicine and genomic profiling are key. They help doctors tailor treatments to each patient’s needs.

Shifting Paradigms in Oncology

Oncology is seeing a big change, thanks to new tech and strategies. We’re moving towards treatments that focus on each patient’s unique cancer. This is a more patient-centric approach.

This shift also means more focus on preventive care and early treatment. We’re working on combination therapies that target cancer more effectively.

Immunotherapy: Leading the Charge Against Cancer

Which Treatment Would Most Likely Be Used for Cancer 2025?
Which Treatment Would Most Likely Be Used for Cancer 2025? 6

The fight against cancer is getting a boost from immunotherapy. This new method uses the body’s immune system to attack cancer. It’s a big step towards better treatments and longer lives for patients.

Immune Checkpoint Inhibitors

Immune checkpoint inhibitors are making waves in cancer treatment. They help the immune system fight cancer cells more effectively. Experts say these drugs have changed the game, leading to better survival rates

Bispecific Antibodies and Immune Modulators

Bispecific antibodies and immune modulators are also making a difference. They help the immune system find and attack cancer cells better. Bispecific antibodies, for instance, can target two different points on cancer cells at once.

Overcoming Resistance to Immunotherapy

But there’s a big hurdle: overcoming resistance. Researchers are racing to find ways to beat this challenge. They aim to make immunotherapy even more effective. We’re all in on this effort to improve treatment results.

“The future of cancer treatment lies in our ability to harness the power of the immune system effectively. Immunotherapy represents a significant step forward in this journey.”

CAR T-Cell Therapy: Engineering Immune Cells to Fight Cancer

Engineered immune cells are changing cancer treatment with CAR T-cell therapy. This method modifies a patient’s T-cells to better fight cancer cells.

Expanding Applications Beyond Blood Cancers

At first, CAR T-cell therapy was a big hope for blood cancers, with some patients seeing their cancer disappear. Now, scientists are looking into using it for solid tumors too. This could help more people get better treatment.

Researchers are checking if CAR T-cell therapy can work on different cancers. This is important because it could give more people a chance at beating their cancer.

Advancements in CAR T-Cell Production and Delivery

Big steps are being taken to make CAR T-cell therapy better. These changes aim to make the treatment easier to get and faster to make.

New tech and simpler ways to make CAR T-cells are being developed. These changes help get the therapy to patients quicker and make it cheaper.

Managing and Reducing Treatment-Related Toxicities

Even though CAR T-cell therapy is very effective, dealing with side effects is key. Scientists are trying to find ways to lessen these side effects. This way, patients can enjoy the benefits of the treatment without too many problems.

One big challenge is cytokine release syndrome (CRS), a serious side effect. Doctors are working on better ways to handle and prevent CRS. This will help make the treatment safer for patients.

Antibody-Drug Conjugates: Precision-Guided Cancer Missiles

Antibody-drug conjugates (ADCs) are changing cancer treatment. They use antibodies to find cancer cells and then deliver drugs to kill them. This makes them a powerful tool against cancer.

Advancements in ADC Technology

New ADC targets and better linker technologies are making these treatments more effective. Scientists are finding new antigens on cancer cells to target. For example, Trastuzumab deruxtecan targets HER2-positive breast cancer and has shown great results in trials.

Linker technologies are also key. They keep the drug stable until it reaches cancer cells. This ensures the drug hits its mark, reducing harm to healthy cells.

Clinical Benefits and Reduced Side Effects

ADCs offer a big advantage over traditional chemotherapy. They target cancer cells directly, reducing harm to healthy tissues. This leads to fewer side effects and better results for patients.

“The precision of ADCs represents a paradigm shift in cancer treatment, providing patients with more effective and tolerable therapies.” –

  • Senior Oncologist

Studies have shown ADCs work well against many cancers, including blood cancers and solid tumors. For instance, Brentuximab vedotin is approved for certain types of lymphoma.

FDA Approvals and Clinical Implementation

The FDA has approved several ADCs for cancer treatment. More are in development. As they get approved, they become more available, giving hope to patients with few options.

ADCTargetApproved Indications
Trastuzumab deruxtecanHER2HER2-positive breast cancer
Brentuximab vedotinCD30Relapsed or refractory Hodgkin lymphoma, systemic anaplastic large cell lymphoma
Inotuzumab ozogamicinCD22Relapsed or refractory B-cell precursor acute lymphoblastic leukemia

As research keeps improving, we’ll see more ADCs in use. This will help fight cancer even more effectively.

Which Treatment Would Most Likely Be Used for Cancer in Different Types and Stages

Understanding cancer types and stages is key to effective treatment. Cancer is complex, needing different treatments based on its type and stage. This includes solid tumors and hematological malignancies.

Solid Tumors vs. Hematological Malignancies

Solid tumors, like those in breast, lung, and colon cancers, often need surgery and radiation. They also get systemic treatments. Hematological malignancies, like leukemias and lymphomas, mainly receive systemic treatments like chemotherapy and immunotherapy.

For example, someone with early-stage breast cancer might get surgery, then radiation and hormone therapy. But someone with acute myeloid leukemia (AML) might get intense chemotherapy and possibly a bone marrow transplant.

Early-Stage vs. Advanced Cancer Treatment Approaches

The stage of cancer is very important for treatment. Early-stage cancers aim for a cure with surgery or radiation. Sometimes, they also get systemic treatments.

Advanced cancers need a focus on controlling the disease and easing symptoms. Treatments include chemotherapy, targeted therapy, and immunotherapy, often together.

“The treatment of cancer has become increasingly complex, requiring a multidisciplinary approach to address the unique needs of each patient.”

  • Senior Oncologist

Pediatric Cancer Treatment Innovations

Pediatric cancers are unique, needing treatments that minimize side effects and aim for high cure rates. New treatments include targeted therapies and immunotherapies, showing great promise.

  • Targeted therapies that focus on specific genetic mutations
  • Immunotherapies, such as CAR T-cell therapy, have shown significant efficacy in certain pediatric leukemias
  • Precision medicine approaches that tailor treatment to the individual child’s genetic profile

Rare Cancer Treatment Strategies

Rare cancers are hard to treat because of their low occurrence and limited research. Treatment often combines standard therapies and clinical trials.

Cancer TypeCommon TreatmentsEmerging Therapies
Solid TumorsSurgery, Radiation Therapy, ChemotherapyImmunotherapy, Targeted Therapy
Hematological MalignanciesChemotherapy, Targeted Therapy, Bone Marrow TransplantCAR T-cell Therapy, Bispecific Antibodies
Pediatric CancersChemotherapy, Surgery, Radiation TherapyTargeted Therapies, Immunotherapies
Rare CancersCombination of standard therapies, Clinical TrialsPrecision Medicine, Novel Targeted Therapies

In conclusion, cancer treatment is complex, depending on the type and stage. As research advances, we’ll see more targeted and effective treatments. This will improve outcomes for patients with different cancers.

Targeted Therapies and Molecular Inhibitors

Our understanding of cancer biology is growing. Targeted therapies and molecular inhibitors are key to new treatments. They aim at specific changes in cancer cells, making treatments more precise than before.

Small Molecule Inhibitors for Specific Mutations

Small molecule inhibitors are a big step forward in cancer treatment. For example, KRASG12C inhibitors are helping patients with certain cancer mutations. Research at MD Anderson shows these inhibitors offer new hope to many.

“The creation of targeted therapies like KRASG12C inhibitors is a major leap in cancer treatment,” says a top oncologist. “They target cancer’s specific mutations, leading to better treatments with fewer side effects.”

Targeting Cancer Metabolism and Microenvironment

Researchers are also looking into cancer metabolism and the tumor microenvironment. Cancer cells have different metabolic needs that help them grow fast. By attacking these needs, we can cut off cancer’s food supply.

  • Targeting glucose metabolism in cancer cells
  • Inhibiting angiogenesis to prevent tumor growth
  • Modulating the immune response within the tumor microenvironment

Overcoming Resistance Mechanisms

Targeted therapies face a big challenge: overcoming resistance. Cancer cells can resist these treatments in many ways. Scientists are working hard to understand and beat these resistance tactics.

Using different targeted therapies together or with other treatments like immunotherapy can help. Physician says, “The secret to beating cancer is to keep changing and improving our treatments to outsmart cancer’s defenses.”

Precision Medicine and Genomic Profiling

Precision medicine, led by genomic profiling, is changing cancer care. We’re seeing a big move towards treatments that fit each person better. This is because we now understand tumors’ genetic makeup better.

Comprehensive Tumor Sequencing

Comprehensive tumor sequencing is key in fighting cancer. It gives us insights into what makes cancer grow. We can then make treatments that target these specific changes, helping patients more.

Tumor sequencing looks at cancer cells’ DNA to find mutations for therapy. This method is showing great promise, even in cancers with tough outlooks.

Liquid Biopsies for Real-Time Monitoring

Liquid biopsies let us check on cancer without invasive tests. They look at DNA in blood to see how cancer is changing. This helps us adjust treatments as needed.

Liquid biopsies are changing how we watch cancer. They let us check more often and with less pain than old methods. This means we can act fast when the tumor changes.

Pharmacogenomics in Treatment Selection

Pharmacogenomics helps pick the right treatment for each patient. It looks at genes that affect how drugs work. This way, we can avoid bad reactions and get better results.

Using pharmacogenomics in medicine is making treatments more precise. It helps us choose the best treatments, doses, and avoid drug interactions.

As we keep improving in precision medicine and genomic profiling, we’re getting closer to a future where cancer treatment is perfect for each person. These new technologies will help us make treatments better and improve patients’ lives.

Artificial Intelligence in Cancer Treatment Decision-Making

AI is changing cancer care by making diagnoses more accurate and treatments more effective. As we use more AI in oncology, we see big improvements in cancer treatment.

Enhancing Diagnostic Accuracy

AI tools are changing how we find cancer. They look at lots of medical data to spot patterns humans might miss. For example, AI can predict lung and breast cancer years early, just like doctors.

“AI has the power to change cancer diagnosis. It makes diagnoses more accurate and faster, leading to better patient results.”

These AI tools also help doctors by doing less work. This lets them focus on harder cases.

Predicting Treatment Response

AI is also great at predicting how well a treatment will work. It looks at data like genetic profiles and past treatment results. This helps us make treatment plans that fit each patient better.

Treatment ModalityAI Predictive CapabilityPotential Outcome
ChemotherapyPredicting response based on genomic dataPersonalized treatment plans
ImmunotherapyIdentifying possible respondersImproved treatment success
Targeted TherapyMatching patients with the right targetsBetter treatment results

Streamlining Clinical Trial Matching

Machine learning helps match patients with clinical trials. This speeds up trials and makes sure patients get treatments that work best for them.

As AI gets better, we’ll see more new uses in cancer care. The future of cancer treatment will be shaped by AI. We’ll see more effective, personalized, and caring care for patients everywhere.

Conclusion: The Promising Future of Cancer Care in 2025

Looking ahead to 2025, the future of cancer care is bright. New treatments like immunotherapies, targeted therapies, and precision medicine are changing how we fight cancer. These advancements mean better, more personalized care for patients.

Immunotherapies, such as immune checkpoint inhibitors and CAR T-cell therapy, are showing great results. Targeted therapies, like antibody-drug conjugates and molecular inhibitors, are also making a big difference. Precision medicine and genomic profiling help doctors tailor treatments to each patient.

The future of cancer treatment is looking up, thanks to ongoing research and clinical trials. We can expect even better results for patients. Places like MD Anderson and BC Cancer are leading the way in this progress.

As we move forward, new technologies like artificial intelligence will make cancer care even better. This brings hope to patients and families around the world. We’re excited to see how these advancements will change lives.

FAQ

Which cancer treatments are most likely to be used in 2025?

In 2025, we’ll see more immunotherapies, targeted therapies, and precision medicine. These treatments aim to offer personalized and effective care.

What is immunotherapy, and how does it work?

Immunotherapy uses the immune system to fight cancer. It includes immune checkpoint inhibitors, bispecific antibodies, and immune modulators.

What is CAR T-cell therapy and its applications?

CAR T-cell therapy engineers immune cells to attack cancer. It started with blood cancers but is now used for other cancers, showing great results.

How do antibody-drug conjugates (ADCs) work in cancer treatment?

ADCs are like precision-guided missiles that target cancer cells. They’re designed to minimize harm to healthy cells. New targets and technologies are being explored to improve their effectiveness.

How does the type and stage of cancer affect treatment?

The type and stage of cancer greatly influence treatment. Different methods are needed for solid tumors and blood cancers, and for early and advanced stages.

What is precision medicine and its role in cancer care?

Precision medicine uses tumor sequencing, liquid biopsies, and pharmacogenomics to guide treatment. This approach aims to improve patient outcomes and tailor care to each individual.

How is artificial intelligence (AI) being used in cancer treatment?

AI is transforming cancer care by improving treatment decisions. AI tools, predictive analytics, and machine learning are being used to enhance patient outcomes.

What are the challenges in cancer treatment that researchers are working to overcome?

Researchers are tackling challenges like resistance to immunotherapy and managing treatment side effects. They’re also working to overcome resistance in targeted therapies.

What is the future of cancer care?

The future of cancer care looks promising. Ongoing research and clinical trials aim to improve outcomes. The use of innovative technologies like AI will continue to offer hope to patients worldwide.


References:

  1. Baradaran-Salimi K, Wielepp T, Wiest R, et al. Brain perfusion SPECT in the presurgical evaluation of drug-resistant epilepsy: Estimating the rate of high-confidence seizure onset zone candidates. Epilepsy Res. 2024;205:107432. https://pmc.ncbi.nlm.nih.gov/articles/PMC11393367/

i

Medical Disclaimer

The content on this page is for informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Always consult a qualified healthcare provider regarding any medical conditions.

Book a Free Certified Online
Doctor Consultation

Clinics/branches
GDPR

We're Here to Help.
Get in Touch

Send us all your questions or requests, and our
expert team will assist you.

Our Doctors

Assoc. Prof. MD. Evrim Duman Radiation Oncology

Assoc. Prof. MD. Evrim Duman

Liv Hospital Ulus
Asst. Prof. MD. Meltem Topalgökçeli Selam Medical Oncology

Asst. Prof. MD. Meltem Topalgökçeli Selam

Liv Hospital Ulus
Prof. MD. Duygu Derin Medical Oncology

Prof. MD. Duygu Derin

Liv Hospital Ulus
Prof. MD. Emre Merdan Fayda Radiation Oncology

Prof. MD. Emre Merdan Fayda

Liv Hospital Ulus
Prof. MD. Mehmet Hilmi Doğu Hematology

Prof. MD. Mehmet Hilmi Doğu

Liv Hospital Ulus
Liv Hospital Bahçeşehir
Prof. MD. Meral Günaldı Medical Oncology

Prof. MD. Meral Günaldı

Liv Hospital Ulus
Assoc. Prof. MD. Murat Ayhan Medical Oncology

Assoc. Prof. MD. Murat Ayhan

Liv Hospital Vadistanbul
Prof. MD.  Itır Şirinoğlu Demiriz Hematology

Prof. MD. Itır Şirinoğlu Demiriz

Liv Hospital Vadistanbul
Prof. MD. Tülin Tıraje Celkan Pediatric Hematology and Oncology

Prof. MD. Tülin Tıraje Celkan

Liv Hospital Vadistanbul
Assoc. Prof. MD. Erkan Kayıkçıoğlu Medical Oncology

Assoc. Prof. MD. Erkan Kayıkçıoğlu

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Mine Dağgez Gynecological Oncology

Assoc. Prof. MD. Mine Dağgez

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Ozan Balakan Medical Oncology

Assoc. Prof. MD. Ozan Balakan

Liv Hospital Bahçeşehir
MD. Taylan Bükülmez Radiation Oncology

MD. Taylan Bükülmez

Liv Hospital Bahçeşehir
Op. MD. Alp Koray Kinter Gynecological Oncology

Op. MD. Alp Koray Kinter

Liv Hospital Bahçeşehir
Prof. MD. Nuri Faruk Aykan Medical Oncology

Prof. MD. Nuri Faruk Aykan

Liv Hospital Bahçeşehir
Prof. MD. Yasemin Altuner Torun Pediatric Hematology and Oncology

Prof. MD. Yasemin Altuner Torun

Liv Hospital Bahçeşehir
Spec. MD. Özlem Doğan Medical Oncology

Spec. MD. Özlem Doğan

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Emir Çelik Medical Oncology

Assoc. Prof. MD. Emir Çelik

Liv Hospital Topkapı
Assoc. Prof. MD. Muhammed Mustafa Atcı Medical Oncology

Assoc. Prof. MD. Muhammed Mustafa Atcı

Liv Hospital Topkapı
Prof. MD. İrfan Çiçin Medical Oncology

Prof. MD. İrfan Çiçin

Liv Hospital Topkapı
Assoc. Prof. MD.  Ramazan Öcal Hematology

Assoc. Prof. MD. Ramazan Öcal

Liv Hospital Ankara
Assoc. Prof. MD. Nazlı Topfedaisi Özkan Gynecological Oncology

Assoc. Prof. MD. Nazlı Topfedaisi Özkan

Liv Hospital Ankara
Prof. MD. Fikret Arpacı Medical Oncology

Prof. MD. Fikret Arpacı

Liv Hospital Ankara
Prof. MD. Gökhan Erdem Medical Oncology

Prof. MD. Gökhan Erdem

Liv Hospital Ankara
Prof. MD. Meral Beksaç Hematology

Prof. MD. Meral Beksaç

Liv Hospital Ankara
Prof. MD. Oral Nevruz Hematology

Prof. MD. Oral Nevruz

Liv Hospital Ankara
Prof. MD. Saadettin Kılıçkap Medical Oncology

Prof. MD. Saadettin Kılıçkap

Liv Hospital Ankara
Prof. MD. Sadık Muallaoğlu Medical Oncology

Prof. MD. Sadık Muallaoğlu

Liv Hospital Ankara
Spec. MD. Ender Kalacı Medical Oncology

Spec. MD. Ender Kalacı

Liv Hospital Ankara
Assoc. Prof. MD. Fadime Ersoy Dursun Hematology

Assoc. Prof. MD. Fadime Ersoy Dursun

Liv Hospital Gaziantep
Prof. MD. Fatih Teker Medical Oncology

Prof. MD. Fatih Teker

Liv Hospital Gaziantep
Spec. MD. ELXAN MEMMEDOV Medical Oncology

Spec. MD. ELXAN MEMMEDOV

Liv Bona Dea Hospital Bakü
Spec. MD. Ceyda Aslan Hematology

Spec. MD. Ceyda Aslan

Spec. MD. Elkhan Mammadov Medical Oncology

Spec. MD. Elkhan Mammadov

Spec. MD. Elmir İsrafilov Hematology

Spec. MD. Elmir İsrafilov

Spec. MD. Minure Abışova Eliyeva Hematology

Spec. MD. Minure Abışova Eliyeva

Spec. MD. Natavan Azizova Medical Oncology

Spec. MD. Natavan Azizova

Need Help? Chat with our medical team

Let's Talk on WhatsApp

📌

Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.

or call us at +90 530 174 42 01